MAPT and tauopathy: If confirmed by multicenter trials in larger samples, the assessment of tauopathy using Tau PET imaging may improve the patient management and our knowledge concerning the neurological alterations beyond the disease, including a view of the timeline of neurological changes in atypical presentations of AD.